Poly ureaurethane Brand Name– Nuvail
What is Poly ureaurethane
Poly ureaurethane is a biocompatible, polymeric solution that is applied topically to the nails.
It Poly-ureaurethane coats and adheres to the nail surface, providing a flexible, waterproof barrier film that protects against the effects of moisture, abrasion, and friction, thus improving fragile, splitting nails (nail dystrophy). It may be used for intact or damaged nails.
The film wears off naturally and must be re-applied as directed to be effective
Indications
- nail dystrophy
For management of the signs and symptoms of nail dystrophy, i.e., nail splitting and nail fragility, for intact or damaged nails
Mechanism of Action
Poly-ureaurethane is a biocompatible, polymeric solution that forms a waterproof barrier when applied to the nail. This barrier prevents direct abrasion and friction on the nail surface and protects against the effects of moisture.
Pharmacokinetics
Poly-ureaurethane is applied topically to the fingernail; clinically significant systemic absorption is not expected.
What are the side effects of Poly ureaurethane
- erythema
- skin irritation
Poly-ureaurethane may cause stinging upon application. Instruct patients to discontinue use and consult a healthcare provider if redness/erythema or other signs of skin irritation occur.
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- bleeding
- breast-feeding
- pregnancy
Patients with isocyanate hypersensitivity should not use poly-ureaurethane.
Interactions
There are no drug interactions associated with Poly-ureaurethane products.
Pregnancy
Information regarding the use of poly-ureaurethane during pregnancy is not provided by the manufacturer. However, because the solution is applied topically to the nail, clinically significant systemic absorption would not be expected.
Lactation
Information regarding the use of poly-ureaurethane during breast-feeding is not provided by the manufacturer. However, because the solution is applied topically to the nail, clinically significant systemic absorption would not be expected. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
